as 11-21-2024 4:00pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | BERKELEY HEIGHTS |
Market Cap: | 626.8M | IPO Year: | 2010 |
Target Price: | $15.20 | AVG Volume (30 days): | 1.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.80 | EPS Growth: | N/A |
52 Week Low/High: | $2.89 - $13.85 | Next Earning Date: | 10-30-2024 |
Revenue: | $12,262,234 | Revenue Growth: | 41184.20% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 277.75% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Masson-Hurlburt Elizabeth | CRMD | EVP | Nov 14 '24 | Sell | $11.18 | 140,027 | $1,565,669.89 | 45,397 |
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Simply Wall St.
18 days ago
Simply Wall St.
21 days ago
GuruFocus.com
22 days ago
GlobeNewswire
23 days ago
GuruFocus.com
24 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.